DATE: August 18, 2020
TIME: 6:00am PDT, 9:00am EDT
More than 250 HPV tests and hundreds of different variants are commercially available globally, but majority of these tests do not meet the performance characteristic standards agreed upon in the HPV community or have analytical or clinical evaluation data published in peer reviewed journals. HPV test performance can be determined in multiple different ways, but the most widely adopted guideline is the 2009 international consensus on minimal requirements that HPV tests needs to meet so they can be safely used in clinical practice. Besides these, VALGENT, initiated in 2012, provides a formalized and uniform study framework that enables comparison and validation of HPV assays with genotyping capability. Alinity m HR HPV assay is the 14th assay that has been evaluated using the VALGENT-3 framework. Within the study, risk stratification using Alinity m HR HPV assay was determined as well.
- Understand how Alinity m meets the 2009 international consensus guidelines on test requirements for primary cervical cancer screening
- Demonstrate performance characteristics of Alinity m HR HPV assay in the VALGENT-3 framework
- Assess the importance of extended genotyping to evaluate risk and triage patients effectively
Webinars will be available for unlimited on-demand viewing after live event.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.